Second primary malignancies represent small proportion of adverse events after CAR T-cell therapy
Second primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according to a letter to the editor published online ...
Mar 20, 2024
0
0